Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among Texas medicaid patients with persistent asthma

Journal of Managed Care Pharmacy

Volumn 21, Issue 12, 2015, Pages 1124-1132

  Makhinova, Tatiana ^a   Barner, Jamie C ^a   Richards, Kristin M ^a   Rascati, Karen L ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; MOMETASONE FUROATE; MONTELUKAST; SALMETEROL; TRIAMCINOLONE; ZAFIRLUKAST; ZILEUTON; ANTIASTHMATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICATION COMPLIANCE; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES; AFRICAN AMERICAN; CONTROLLED STUDY; ETHNICITY; HISPANIC; OUTCOME VARIABLE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; DISEASE COURSE; DRUG EFFECTS; DRUG SUBSTITUTION; FACTUAL DATABASE; HEALTH INSURANCE; LUNG; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RISK FACTOR; SALVAGE THERAPY; STATISTICAL MODEL; TEXAS; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DISEASE PROGRESSION; DRUG SUBSTITUTION; FEMALE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LINEAR MODELS; LOGISTIC MODELS; LUNG; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; TEXAS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84948966805     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.12.1124     Document Type: Article

References (61)

1. National Center for Health Statistics. National Health Interview Survey (NHIS). 2009 data release. Centers for Disease Control and Prevention. 2010. Page updated December 14, 2012. Available at: http://www.cdc.gov/ nchs/nhis/nhis_2009_data_release.htm. Accessed October 14, 2015.
2. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma. Summary report 2007. NIH Publication Number 08-5846. October 2007.Available at: http://www.nhlbi.nih.gov/files/docs/guidelines/asthsumm.pdf. Accessed October 14, 2015.
3. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114(6):1288-93.
4. Lasmar L, Camargos P, Champs NS, et al. Adherence rate to inhaled corticosteroids and their impact on asthma control. Allergy. 2009;64(5):784-89.
5. Williams LK, Joseph CL, Peterson EL, et al. Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol. 2007;120(5):1153-59.
6. Kandane-Rathnayake RK, Matheson MC, Simpson JA, et al. Adherence to asthma management guidelines by middle-aged adults with current asthma. Thorax. 2009;64(12):1025-31.
7. Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol. 2006;118(4):899-904.
8. Camargo CA, Ramachandran S, Ryskina KL, Lewis BE, Legoretta AP. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am J Health Syst Pharm. 2007;64(10):1054-61.
9. Herndon JB, Mattke S, Cuellar AE, Hong SY, Shenkman EA. Anti-inflammatory medication adherence, healthcare utilization and expenditures among medicaid and children's health insurance program enrollees with asthma. Pharmacoeconomics. 2012;30(5):397-412.
10. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180(9):817-22.
11. Desai M, Oppenheimer JJ. Medication adherence in the asthmatic child and adolescent. Curr Allergy Asthma Rep. 2011;11(6):454-64.
12. Jentzsch NS, Camargos PAM, Colosimo EA, Bousquet J. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy. 2009;64(10):1458-62.
13. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2005;25(1):107-30.
14. Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma. 2003;40(1):93-101.
15. Bozek A, Jarzab J. Adherence to asthma therapy in elderly patients. J Asthma. 2010;47(2):162-65.
16. Latry P, Pinet M, Labat A, et al. Adherence to anti-inflammatory treatment for asthma in clinical practice in France. Clin Ther. 2008;30 (Spec No):1058-68.
17. McNally KA, Rohan J, Schluchter M, et al. Adherence to combined montelukast and fluticasone treatment in economically disadvantaged African American youth with asthma. J Asthma. 2009;46(9):921-27.
18. Delea TE, Stanford RH, Hagiwara M, Stempel DA. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Curr Med Res Opin. 2008;24(12):3435-42.
19. Mattke S, Martorell F, Hong SY, Sharma P, Cuellar A, Lurie N. Anti-inflammatory medication adherence and cost and utilization of asthma care in a commercially insured population. J Asthma. 2010;47(3):323-29.
20. Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185-191.e2.
21. Stern L, Berman J, Lumry W, et al. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Ann Allergy Asthma Immunol. 2006;97(3):402-08.
22. Tan H, Sarawate C, Singer J, et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc. 2009;84(8):675-84.
23. Elkout H, Helms PJ, Simpson CR, McLay JS. Adequate levels of adherence with controller medication is associated with increased use of rescue medication in asthmatic children. PLoS One. 2012;7(6):e39130.
24. Lee TA, Chang CL, Stephenson JJ, et al. Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients. Curr Med Res Opin. 2010;26(12):2851-60.
25. Wong MD, Manley RT, Stettin G, Chen W, Salmun LS. Intervention to reduce unnecessary dispensing of short-acting {beta}-agonists in patients with asthma. Ann Pharmacother. 2010;44(4):623-29.
26. Schatz M, Stempel D. Asthma quality-of-care measures using administrative data: relationships to subsequent exacerbations in multiple databases. Ann Allergy Asthma Immunol. 2008;101(3):235-39.
27. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention 2014. Available at: http://www.ginasthma.org/local/uploads/ files/GINA_Report_2014_Aug12_1.pdf. Accessed October 14, 2015.
28. Bender B, Zhang L. Negative affect, medication adherence, and asthma control in children. J Allergy Clin Immunol. 2008;122(3):490-95.
29. Burgess SW, Sly PD, Devadason SG. Providing feedback on adherence increases use of preventive medication by asthmatic children. J Asthma. 2010;47(2):198-201.
30. Murphy AC, Proeschal A, Brightling CE, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012;67(8):751-53.
31. Smith K, Warholak T, Armstrong E, Leib M, Rehfeld R, Malone D. Evaluation of risk factors and health outcomes among persons with asthma. J Asthma. 2009;46(3):234-37.
32. National Committee for Quality Assurance. National voluntary consensus standards for physician-focused ambulatory care. Appendix A-NCQA measure technical specifications. April 2008 V.7. Available at: http://www.ncqa.org/Portals/0/HEDISQM/NQF_Posting_Appendix.pdf. Accessed October 26, 2015.
33. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009;12(6):989-95.
34. Stanford RH, Shah MB, D'Souza AO, Dhamane AD, Schatz M. Shortacting beta-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403-07.
35. Schatz M, Zeiger RS, Yang ST, et al. Relationship of asthma control to asthma exacerbations using surrogate markers within a managed care database. Am J Manag Care. 2010;16(5):327-33.
36. Silver HS, Blanchette CM, Kamble S, et al. Quarterly assessment of short-acting beta(2)-adrenergic agonist use as a predictor of subsequent health care use for asthmatic patients in the United States. J Asthma. 2010;47(6):660-66.
37. Blais L, Kettani FZ, Lemière C, et al. Inhaled corticosteroids vs. leukotriene- receptor antagonists and asthma exacerbations in children. Respir Med. 2011;105(6):846-55.
38. Chang J, Freed GL, Prosser LA, et al. Comparison of health care utilization outcomes in children with asthma enrolled in private insurance plans versus Medicaid. J Pediatr Care. 2014;28(1):71-79.
39. Fredrickson DD, Molgaard CA, Dismuke SE, Schukman JS, Walling A. Understanding frequent emergency room use by Medicaid-insured children with asthma: a combined quantitative and qualitative study. J Am Board Fam Pract. 2004;17(2):96-100.
40. Piecoro LT, Potoski M, Talbert JC, Doherty DE. Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population. Health Serv Res. 2001;36(2):357-71.
41. Lieu TA, Lozano P, Finkelstein JA, et al. Racial/ethnic variation in asthma status and management practices among children in managed Medicaid. Pediatrics. 2002;109(5):857-65.
42. Claudio L, Stingone JA. Primary household language and asthma care among Latino children. J Health Care Poor Underserved. 2009;20(3):766-79.
43. McQualid EL, Everhart RS, Seifer R, et al. Medication adherence among Latino and non-Latino white children with asthma. Pediatrics. 2012;129(6):e1404-10.
44. Kit BK, Simon AE, Ogden CL, Akinbami LJ. Trends in preventive asthma medication use among children and adolescents, 1988-2008. Pediatrics. 2012;129(1):62-69.
45. Wishnivesky JP, Kattan M, Evans D, et al. Assessing the relationship between language profficiency and asthma morbidity among inner-city asthmatics. Med Care. 2009;47(2):243-49.
46. Lob SH, Holloman Boer J, Porter PG, Núñez D, Fox P. Promoting bestcare practices in childhood asthma: quality improvement in community health centeres. Pediatrics. 2011;128(1):20-28.
47. Mosnaim G, Li H, Martin M, et al. A tailored mobile health intervention to improve adherence and asthma control in minority adolescents. J Allergy Clin Immunol Pract. 2015;3(2):288-90.e1.
48. Reznik M, Silver EJ, Cao Y. Evaluation of MDI spacer utilization and technique in caregivers of urban minority children with persistent asthma. J Asthma. 2014;51(2):149-54.
49. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012;308(10):987-97.
50. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005;352(15):1519-28.
51. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040-52.
52. O'Connor GT, Reibman J. Inhaled corticosteroid dose adjustment in mild persistent asthma. JAMA. 2012;308(10):1036-37.
53. Oladapo AO, Barner JC, Rascati KL, Strassels SA. A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid. Clin Ther. 2012;34(3):605-13.
54. Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin. 2011;27(Suppl 2):13-22.
55. Paris J, Peterson EL, Wells K, et al. Relationship between recent shortacting beta-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol. 2008;101(5):482-87.
56. Ducharme FM, Nova FJ, Allen-Ramey FC, Maiese EM, Gingras J, Blais L. Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Res Opin. 2012;28(1):111-19.
57. Broder MS, Chang EY, Kamath T, Sapra S. Poor disease control among insured users of high-dose combination therapy for asthma. Allergy Asthma Proc. 2010;31(1):60-67.
58. Butz AM, Tsoukleris M, Donithan M, et al. Patterns of inhaled antiinflammatory medication use in young underserved children with asthma. Pediatrics. 2006;118(6):2504-13.
59. Walders N, Kopel SJ, Koinis-Mitchell D, McQuaid EL, et al. Patterns of quick-relief and long-term controller medication use in pediatric asthma. J Pediatr. 2005;146(2):177-82.
60. Allen-Ramey FC, Bukstein D, Luskin A, Sajjan SG, Markson LE. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. J Manag Care Pharm. 2006;12(4):310-21. Available at: http://amcp.org/data/jmcp/310-321.pdf.
61. Zeiger R, Schatz M, Li Q, et al. Real-time asthma outreach reduces excessive short-acting ß2-agonist use: a randomized study. J Allergy Clin Immunol Pract. 2014;2(4):445-56.